Cite
HARVARD Citation
Ushijima, M. et al. (2022). An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. Cancer science. 113 (5), pp. 1731-1738. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ushijima, M. et al. (2022). An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. Cancer science. 113 (5), pp. 1731-1738. [Online].